Barclays
DXCM icon

Barclays’s DexCom DXCM Stock Holding History

Barclays’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$100K – 5146
2025
Q4 		$100K Sell
1,500
-34,900
-96% -$2.26M ﹤0.01% 4585
2025
Q3 		$2.45M Sell
36,400
-27,400
-43% -$2.17M ﹤0.01% 2736
2025
Q2 		$5.57M Buy
63,800
+28,800
+82% +$2.26M ﹤0.01% 2031
2025
Q1 		$2.39M Hold
35,000
– – ﹤0.01% 2494
2024
Q4 		$2.72M Hold
35,000
– – ﹤0.01% 2666
2024
Q3 		$2.35M Buy
+35,000
New +$2.87M ﹤0.01% 2725
2024
Q2 		– Sell
-35,500
Closed -$4.92M – 4983
2024
Q1 		$4.92M Sell
35,500
-213,200
-86% -$26.8M ﹤0.01% 1866
2023
Q4 		$30.9M Buy
+248,700
New +$25.4M 0.01% 880
2023
Q2 		– Sell
-175,500
Closed -$20.4M – 4672
2023
Q1 		$20.4M Sell
175,500
-3,700
-2% -$414K 0.01% 834
2022
Q4 		$20.3M Buy
+179,200
New +$19.7M 0.01% 884
2022
Q1 		– Sell
-20,400
Closed -$2.74M – 5108
2021
Q4 		$2.74M Buy
+20,400
New +$2.93M ﹤0.01% 2170
2020
Q2 		– Sell
-400
Closed -$27K – 5704
2020
Q1 		$27K Buy
+400
New +$24.9K ﹤0.01% 5534
2019
Q3 		– Sell
-160,000
Closed -$5.99M – 6792
2019
Q2 		$5.99M Buy
+160,000
New +$5.03M ﹤0.01% 1706
2018
Q4 		– Sell
-90,000
Closed -$3.22M – 7022
2018
Q3 		$3.22M Sell
90,000
-110,000
-55% -$3.41M ﹤0.01% 2317
2018
Q2 		$4.75M Buy
200,000
+196,000
+4,900% +$4.16M ﹤0.01% 1764
2018
Q1 		$74K Sell
4,000
-52,800
-93% -$781K ﹤0.01% 5601
2017
Q4 		$815K Buy
56,800
+54,800
+2,740% +$712K ﹤0.01% 3319
2017
Q3 		$24K Sell
2,000
-82,800
-98% -$1.46M ﹤0.01% 5713
2017
Q2 		$1.55M Buy
84,800
+83,600
+6,967% +$1.54M ﹤0.01% 2479
2017
Q1 		$25K Buy
+1,200
New +$23.4K ﹤0.01% 5702
2013
Q4 		– Sell
-45,600
Closed -$319K – 7565
2013
Q3 		$319K Buy
+45,600
New +$289K ﹤0.01% 4574

Other funds holding DXCM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Barclays's DXCM Position: Q3 2026 in Review

Barclays increased its DexCom (DXCM) stake by 18% in Q3 2026, buying an estimated $14.9M and bringing the position to 1,178,516 shares worth $102M. The position accounts for 0.02% of the portfolio, ranked #497.

Barclays first reported a position in DXCM in Q2 2013 and has held it in 54 quarters since. The position peaked at $178M in Q1 2024. 516 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Barclays held 1,178,516 shares of DexCom worth $102M as of Q3 2026.
  • Barclays bought 178,953 DexCom shares in Q3 2026, an estimated $14.9M.
  • DexCom made up 0.02% of Barclays's portfolio in Q3 2026, its #497 holding.
  • Barclays first reported a position in DexCom in Q2 2013 and has held it in 54 quarters since.
  • Barclays's DexCom position peaked at $178M in Q1 2024.
  • 516 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.